Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.

Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

In the first three quarters of 2022, the company achieved revenue of CNY 1.18 billion, an increase of 39.32% year-on-year; net profit of CNY 308 million, an increase of 22.42% year-on-year; net profit of CNY 306 million, an increase of 28.84% year-on-year.

Qiagen reported double-digit year-over-year sales growth in its core non-COVID-related product portfolio on Monday afternoon, prompting the company to raise its full-year guidance.

Cepheid said Monday it secured CE-IVD marking for its group B Streptococcus assay, Xpert Xpress GBS, and will start selling the test in Europe this month.

As a leading enterprise in China's in vitro diagnostic industry, Autobio Diagnostics CO.,Ltd. has continued to maintain a steady growth trend.

Illumina, Inc. (Nasdaq: ILMN) today announced its financial results for the third quarter of fiscal year 2022, which include consolidated financial results for GRAIL.

For its first full quarter following a business combination, QuidelOrtho after the close of the market on Wednesday reported third-quarter revenues of $783.8 million, an increase of 54% compared to $509.8 million in Q3 2021 and in line with preliminary estimates announced in October.

Snibe announced its 2022 Q3 report, the company achieved operating revenue of RMB 880 million, up 31.67% year-on-year; net profit attributable to shareholders of the listed company was RMB 355 million, up 49.72% year-on-year.

Bruker reported before the open of markets on Thursday that revenues in the third quarter rose 5 percent year over year.

Twist Bioscience said on Tuesday that it has inked a partnership with Illumina to produce the co-branded Twist Bioscience for Illumina Exome 2.0 Plus panel for disease research.

In the evening of October 24, Beijing Hotgen Biotech Co., Ltd. (stock code: 688068) released its third quarter report for 2022. In the third quarter, Hotgen 's revenue and net profit continued to jump, achieving CNY 963 million revenue with a year-on-year increase of 391.95%